Steve Projan joined MedImmune in 2010 as Senior Vice President of Research and Development and Innovative Medicines Head for Infectious Diseases & Vaccines. Under his leadership, MedImmune received marketing approval in 2012 for the first quadrivalent influenza vaccine (“FluMist Quad”) and Dr. Projan was named “Pharma Executive of the Year” at the Vaccine Industry Excellence Awards. Prior to joining MedImmune, he spent two years at Novartis as Global Head of Infectious Diseases and 15 years at Wyeth, following a 14-year academic career at the Public Health Research Institute. At Wyeth, Dr. Projan was the Biology Team Leader of the Glycylcycline Discovery Team that produced tigecycline, an antibacterial drug for the treatment of drug-resistant bacterial infections.  Dr. Projan attended and graduated from the Massachusetts Institute of Technology (SB 1974) and Columbia University (MA, MPhil, & PhD 1980).  In 2004, Dr. Projan was named a Fellow of the American Academy of Microbiology. He has authored or co-authored more than 100 publications.